Interviews And Expert Opinions
Why One Doctor Changed His Mind About Medical Marijuana

For decades, cannabis has been classified by the U.S. government as a Schedule I drug—a label reserved for substances with a high potential for abuse and no accepted medical use. But as science catches up with public sentiment and patient advocacy, a growing number of medical professionals are reconsidering long-held beliefs about marijuana. Among the most high-profile is Dr. Sanjay Gupta, who publicly reversed his opposition to medical cannabis after a deep dive into the research—and into the lives of patients for whom cannabis was life-changing.
A Personal and Professional Shift in Perspective
When Dr. Gupta first evaluated the medical cannabis landscape, he was skeptical. The studies available in the U.S. seemed inconclusive or focused mostly on harm. At the time, he supported federal restrictions and wrote against legalization.
But a global investigation for his documentary Weed changed his mind. By interviewing patients, medical professionals, and researchers around the world, Dr. Gupta realized that he—and the broader medical community—had overlooked key data from international studies and dismissed legitimate patient stories.
One of the most compelling cases that swayed his view was that of Charlotte Figi, a young girl with Dravet syndrome, a severe form of epilepsy. After exhausting all conventional treatments, her parents turned to a high-CBD cannabis oil. The result was dramatic: Charlotte’s seizures, which once numbered in the hundreds per week, dropped to just a handful per month.
The Schedule I Dilemma: A Barrier to Science
Cannabis’s classification as a Schedule I substance has severely limited research in the United States. While thousands of studies have been conducted—many highlighting risks and side effects—comparatively few explore therapeutic potential. That imbalance has contributed to the perception that marijuana is more dangerous than it actually is, and made it harder for patients and doctors to access reliable information.
Moreover, U.S. researchers face significant hurdles just to study the plant. They need to obtain government-grown cannabis from a single authorized facility and secure multiple layers of federal approval, including from the National Institute on Drug Abuse (NIDA)—an agency focused more on harm than therapeutic value.
What the Research Really Says
Contrary to longstanding claims, the evidence shows that cannabis has a relatively low potential for abuse compared to other substances. Estimates suggest 9–10% of adult cannabis users may develop a dependency—far lower than the 25% seen with heroin, or the 30% associated with tobacco.
In addition to epilepsy, cannabis has shown promise for managing neuropathic pain, nausea from chemotherapy, and symptoms related to multiple sclerosis. International research has also explored its potential as an anti-inflammatory, neuroprotective agent, and even in some cancer therapies.
Yet most of these studies remain outside the U.S., due in part to legal and institutional barriers.
Misconceptions and Public Health Considerations
Dr. Gupta’s shift didn’t come without concerns. He still urges caution, especially when it comes to youth access. Studies have suggested that frequent cannabis use in adolescence could interfere with brain development and may be linked to cognitive decline. As with alcohol, he believes cannabis use should be delayed until adulthood.
He also highlights risks associated with edibles and potent concentrates. With varying THC levels and inconsistent labeling, new users may unknowingly overconsume—leading to negative experiences like anxiety, paranoia, or nausea. Responsible product regulation and consumer education are crucial to prevent misuse.
A Different Approach to Pain Management
The opioid crisis has underscored the need for alternative pain treatments. Cannabis offers one such path, particularly for conditions that traditional medications often fail to treat effectively. Prescription opioids remain the standard for severe or chronic pain, but their high risk of addiction and overdose has driven both patients and physicians to look for safer solutions.
Unlike opioids, there are no documented cases of death from cannabis overdose. For patients managing long-term pain, especially those with conditions like fibromyalgia or cancer, medical marijuana could provide relief without the same level of risk.
What Comes Next
In the years since his documentary aired, Dr. Gupta has continued to advocate for medical cannabis research and reform. He acknowledges that marijuana isn’t a miracle drug, but it deserves to be studied and used responsibly where appropriate. The growing number of physicians, patients, and researchers calling for change reflects an urgent need to shift cannabis policy from criminal justice to public health.
His conclusion is clear: withholding a potentially beneficial treatment from patients due to outdated laws or stigma is both unethical and medically irresponsible.
Key Takeaways
- Cannabis was classified as a Schedule I drug not because of conclusive harm, but due to a lack of scientific understanding in 1970—a void that remains partially unfilled today.
- International studies and patient experiences point to significant medical benefits of cannabis, especially in treating epilepsy and chronic pain.
- Cannabis has a lower risk of dependency than many legal substances, and its safety profile makes it a compelling alternative to opioids.
- Barriers to research in the U.S. continue to hinder a full understanding of cannabis’s medical applications.
- Responsible regulation, product consistency, and patient education are essential to ensure safe access as legalization continues to spread.
Cannabis Industry News
New York Eyes $1.5 Billion in Cannabis Sales for 2025 as Market Stabilizes

Four years into adult-use cannabis legalization, New York’s legal marijuana industry is finally showing signs of reaching its long-anticipated potential. After a rocky start marked by lawsuits, delays, and illicit market dominance, the state now appears to be entering a more stable and scalable phase—one that could see legal cannabis sales reach $1.5 billion in 2025.
Led by acting Executive Director Felicia Reid, the Office of Cannabis Management (OCM) has spent the past year tightening regulatory processes, accelerating license approvals, and pushing back against illegal operators. While challenges remain, New York’s cannabis sector is beginning to find its footing in what may become one of the country’s most influential cannabis economies.
Legal Cannabis in New York: A Timeline of Challenges
When New York passed the Marihuana Regulation and Taxation Act (MRTA) in March 2021, it made national headlines by promising a cannabis market rooted in social equity, community reinvestment, and restorative justice. The policy vision was bold: prioritize justice-impacted entrepreneurs before allowing large, vertically integrated multistate operators (MSOs) to enter the market.
That vision, while commendable, also led to early complications:
- Legal challenges temporarily blocked license issuance for social equity applicants under the CAURD (Conditional Adult-Use Retail Dispensary) program.
- Limited retail infrastructure meant that cultivation outpaced consumer access, creating a backlog of unsold cannabis products.
- Illicit storefronts flourished, especially in New York City, undercutting licensed businesses.
- A flawed rollout of the state’s social equity fund created confusion and financial delays for licensees.
By the end of 2023, these issues had contributed to widespread skepticism about the state’s cannabis leadership and long-term market viability.
Turning a Corner in 2024
Now, New York is on a different trajectory. As of April 2025, more than 340 legal cannabis retailers are open statewide—up from 260 just four months earlier. Sales surpassed $1 billion in 2024 and are projected to climb to $1.5 billion this year, driven by new store openings and expanding consumer awareness.
Key changes that have enabled this growth include:
- Stronger enforcement against illicit operators, with hundreds of unlicensed storefronts shuttered through coordinated efforts between OCM and law enforcement.
- OCM staffing growth, increasing from 170 to 230 employees in less than a year, allowing faster processing of license applications.
- The launch of the Trade Practices Bureau, a new unit focused on investigating non-compliance among licensed businesses.
- Implementation of youth-centered grants, with $5 million in tax revenue redirected to nonprofit programs in communities impacted by prior cannabis criminalization.
These measures reflect a broader shift in how the state is managing its cannabis industry: more streamlined, more coordinated, and more prepared to support sustained growth.
Social Equity at the Forefront
New York remains committed to its equity-first framework. Justice-impacted individuals and nonprofits were the first to receive licenses, and the state has actively promoted community reinvestment through the Cannabis Revenue Fund.
The CAURD program and broader licensing efforts have granted permits to hundreds of small businesses, helping to build a diverse, locally owned cannabis economy. Through initiatives like the Community Grants Reinvestment Fund and targeted technical assistance, the state is trying to ensure that social equity is more than a slogan—it’s an operational priority.
However, the state is now facing the complex challenge of balancing inclusion with enforcement. In a mixed-market economy that includes both equity and general licensees, regulators are under pressure to maintain fairness while also ensuring regulatory compliance. The OCM’s newly formed Trade Practices Bureau will be instrumental in investigating violations and curbing bad actors within the legal framework.
Retail Growth vs. Cultivation Caution
Although the number of dispensaries continues to increase, the state is taking a more cautious approach to cultivation. As of early 2025, New York has permitted approximately 6.5 million square feet of canopy space for cannabis cultivation, distributed among nearly 200 growers and over 220 microbusinesses.
This expansive production capacity has raised concerns about oversupply, especially if retail access fails to scale proportionately. To prevent price crashes and product surpluses similar to those experienced in other states, the OCM is slowing down approval of new cultivation licenses.
Pending applications from late 2023 remain under review, and some applicants will likely be denied to maintain market balance. The goal is to avoid saturation on the supply side while enabling continued expansion on the retail front.
Ongoing System Gaps
Despite progress, several issues remain unresolved:
- New York still lacks a fully implemented seed-to-sale tracking system, which is required by state law and critical for transparency and diversion prevention.
- Inverted cannabis—product illegally brought in from other states and sold through legal channels—remains a threat to integrity and quality assurance.
- Concerns about THC potency inflation have emerged as testing labs come under scrutiny, mirroring challenges seen in other states.
Furthermore, competition from hemp-derived THC products is creating new headaches for licensed cannabis businesses. These products are widely available, often unregulated, and frequently sold in non-cannabis retail settings like gas stations or convenience stores, providing a cheaper and more accessible alternative.
Policy Decisions That Could Shape the Market
Looking ahead, several factors will determine the success of New York’s cannabis industry:
- Finalizing the track-and-trace system: Without a working system, regulators cannot effectively monitor inventory or prevent diversion.
- Adapting cultivation approvals to actual demand: Keeping supply aligned with consumer purchasing habits will be key to avoiding volatility.
- Ensuring continued social equity support: Funding, training, and ongoing technical assistance will be critical for keeping small and equity-owned businesses competitive.
- Managing hemp product regulations: Policymakers will need to decide whether to limit intoxicating hemp products, which currently undermine the licensed cannabis market.
As the state prepares for another year of potential growth, these policy decisions will directly affect investor confidence, market stability, and consumer trust.
A New Chapter for New York Cannabis
New York’s journey from prohibition epicenter to legal market innovator has been anything but smooth. But the state’s recent progress—reflected in expanding store counts, improved enforcement, and growing sales—signals that the foundational pieces are finally in place.
With projections pointing to $1.5 billion in sales by the end of 2025, New York has the opportunity to become a national leader in cannabis commerce. The key will be maintaining a strategic balance between access, equity, and enforcement.
While no market rollout is perfect, New York’s decision to prioritize justice, reinvestment, and long-term sustainability over short-term profits may ultimately prove to be a defining feature—not a flaw.
Interviews And Expert Opinions
Champ Bailey Shares How Cannabis Helped Sustain His Hall of Fame Career

From lockdown corner to cannabis advocate, NFL legend Champ Bailey is reshaping how the world sees professional athletes and their relationship with plant medicine. After years of playing at the highest level—racking up 12 Pro Bowl selections and cementing his legacy in the Hall of Fame—Bailey is opening up about one of the tools that quietly supported his success: cannabis.
Now a leader at Trulieve, one of the nation’s largest cannabis retailers, Bailey is stepping into the spotlight not just as a former athlete, but as a champion for responsible use and cannabis normalization. His message is simple but powerful: cannabis can be part of a healthy, high-performance lifestyle—and for him, it was a crucial piece of recovery and balance throughout his career.
Cannabis, Recovery, and a New Era of Athletic Wellness
Bailey didn’t discover cannabis until he was already in the league. Raised in the South, he was conditioned to view it through the lens of stigma and legality. But over time, he watched seasoned veterans in the NFL turn to the plant—not for recreation, but for relief. Instead of reaching for alcohol or prescription painkillers, they turned to cannabis to ease the wear and tear of the game.
Bailey followed suit, and what he found was a natural solution to the physical and mental demands of professional football. Post-practice soreness, lingering injuries, and the mental drain of performing under pressure were all eased with a few puffs after a tough day. For Bailey, cannabis wasn’t about getting high—it was about staying grounded.
From Pills to the Plant
During his early years in the NFL, like many players, Bailey was prescribed pharmaceuticals to manage pain. But he soon realized that cannabis provided similar—if not better—relief without the side effects or dependency risks. It became his preferred tool for post-game recovery, and eventually a daily aid for physical and mental wellness.
His story mirrors the broader shift happening in sports medicine, where athletes are moving away from opioids and embracing cannabis as a safer, more sustainable solution. Whether it was a nagging hamstring or a long travel week, cannabis helped him stay focused and functional. It allowed him to keep his edge without sacrificing his health.
A Personal Mission to Destigmatize
Now retired and no longer bound by league restrictions, Bailey is using his platform to share what he couldn’t say during his playing days. At Trulieve, where he serves as Chief Diversity Officer, he’s focused on breaking down stigma, advocating for cannabis access, and encouraging others to explore the plant with intention and responsibility.
Bailey acknowledges that cannabis isn’t for everyone—but believes everyone deserves the choice to explore its benefits without fear or judgment. Through speaking engagements, media interviews, and community engagement, he’s helping normalize the conversation and guide a new generation toward smarter, safer cannabis use.
A Simple Ritual, A Lasting Impact
Despite all the new technology and products in the cannabis space—from edibles to tinctures and vaporizers—Bailey still prefers the simplicity of a joint. For him, it’s about ritual as much as relief. A quiet moment, a few deep breaths, and the opportunity to reset. It’s not about excess—it’s about equilibrium.
And in his home, where he’s also a father, he approaches cannabis with transparency and mindfulness. His kids understand that it’s his medicine—not something taboo, but something to be respected and approached with maturity.
Leading by Example
Bailey’s voice adds much-needed credibility to the cannabis conversation. His Hall of Fame credentials, combined with his thoughtful advocacy, make him a powerful ambassador for the future of cannabis in sports and society. He’s not just talking about policy or reform—he’s living proof that athletes can use cannabis responsibly and still perform at the pinnacle of their profession.
As professional sports continue to evolve, voices like Bailey’s are helping shape a future where cannabis is embraced not just as a wellness tool, but as a pathway to longevity, resilience, and quality of life.
Health And Wellness
How Marijuana (Cannabis) Affects the Body: A Comprehensive Guide

As cannabis becomes more accessible in both medical and recreational settings, it’s increasingly important to understand how this plant affects the human body. Cannabis interacts with multiple systems in complex ways, producing a wide range of effects—some beneficial, others potentially harmful. The outcome depends on how it’s used, who’s using it, and in what context.
This guide explores the short-term and long-term effects of cannabis, with a detailed breakdown of its impact on physical and mental health, as well as specific considerations for younger individuals and pregnant users.
What Is Cannabis and How Is It Used?
Cannabis is a plant that contains a variety of active compounds, the most well-known being:
- THC (delta-9-tetrahydrocannabinol): The main psychoactive component that produces a “high.”
- CBD (cannabidiol): A non-intoxicating compound often used for pain, inflammation, and anxiety relief.
People consume cannabis in several ways, including:
- Smoking (joints, pipes, bongs)
- Vaping (dry flower or oil concentrates)
- Edibles (baked goods, gummies, chocolates)
- Oils and tinctures (sublingual drops)
- Topicals (creams, balms, transdermal patches)
- Teas and beverages
Each method delivers different onset times and durations of effects. Smoking and vaping offer quick relief but may carry respiratory risks, while edibles and oils provide longer-lasting effects but take more time to activate.
Effects on Physical Health
Cannabis can influence many systems in the body, including the nervous, respiratory, immune, and cardiovascular systems. Here’s how it affects physical health:
1. Respiratory System
When inhaled, cannabis smoke can:
- Cause bronchial irritation and chronic cough
- Increase phlegm production
- Exacerbate conditions like asthma or bronchitis
- Introduce combustion byproducts that may damage lung tissue
While cannabis smoke contains fewer carcinogens than tobacco, regular use still carries risk, especially for heavy smokers. Non-combustible forms such as vaporizers or edibles eliminate these respiratory concerns.
2. Immune System
Research suggests THC may suppress immune function, potentially increasing susceptibility to infections. This effect is more pronounced with chronic use and is still being studied in detail.
3. Cardiovascular System
Cannabis can temporarily increase heart rate by 20–50 beats per minute, particularly in inexperienced users or those with existing cardiovascular conditions. Some studies also note elevated blood pressure immediately after consumption, followed by a lowering effect.
4. Eye Health
One of the most visible short-term effects of cannabis is red eyes, caused by increased blood flow. Cannabis may also offer short-term relief for intraocular pressure in glaucoma, though the benefit is temporary and not always clinically recommended.
5. Gastrointestinal Health
Cannabis may relieve nausea and stimulate appetite, which is especially beneficial for people undergoing chemotherapy or dealing with conditions like HIV/AIDS. However, in rare cases, long-term heavy use may lead to cannabinoid hyperemesis syndrome, a condition that causes repeated episodes of severe nausea and vomiting.
Effects on Psychological Health
Cannabis interacts with the brain’s endocannabinoid system, influencing mood, memory, and perception. Effects vary significantly between individuals and are shaped by dosage, strain type, and personal mental health history.
1. Mood and Anxiety
Cannabis can have calming or anxiety-reducing effects in some users, but in others, it may worsen anxiety, cause panic attacks, or trigger paranoia—especially at high doses or in unfamiliar settings.
2. Memory and Cognitive Function
Short-term effects include impairment in short-term memory, attention, and decision-making. These effects typically wear off after the high subsides, but regular long-term use—particularly when started during adolescence—has been linked to long-lasting cognitive decline.
3. Perception and Coordination
Cannabis affects sensory perception and motor coordination, which can impair driving, operating machinery, or performing tasks that require focus. Reaction time is also delayed, posing safety risks in high-responsibility environments.
4. Risk of Dependency
While cannabis is generally considered less addictive than alcohol or opioids, it is possible to develop Cannabis Use Disorder, especially with frequent use over long periods. Symptoms can include cravings, tolerance, withdrawal, and interference with daily activities.
Special Considerations for Younger Users
Cannabis can have particularly strong effects on people under 25 due to ongoing brain development, particularly in areas responsible for decision-making, memory, and impulse control.
1. Adolescents and Teens
Regular cannabis use among teenagers is associated with:
- Reduced academic performance
- Impaired cognitive development
- Higher risk of depression or anxiety disorders later in life
- Potential for long-term memory and attention issues
2. Prenatal Exposure
Cannabis use during pregnancy can affect fetal brain development, leading to potential issues with attention, memory, and behavioral regulation in children. These effects may also carry over into adolescence. Likewise, THC can pass through breast milk, potentially impacting infants’ neurodevelopment.
Long-Term Effects of Cannabis
While many of cannabis’ short-term effects are well understood, the long-term consequences of consistent use are still being researched. Potential outcomes include:
1. Memory and Cognitive Issues
Chronic, heavy cannabis use may lead to persistent memory and concentration problems, particularly in users who started in adolescence.
2. Respiratory Conditions
Long-term smoking may contribute to chronic bronchitis or lung irritation, although a definitive link to lung cancer has not been established due to conflicting data.
3. Mental Health Disorders
Ongoing use, especially in those with a family history of mental illness, may increase the risk of psychosis or schizophrenia. This association is stronger in high-potency THC products and when cannabis is used daily.
4. Cannabinoid Hyperemesis Syndrome (CHS)
This rare but serious condition affects some long-term, high-dose cannabis users and results in recurrent nausea, vomiting, and abdominal pain. Symptoms usually resolve with cessation of cannabis use.
Secondhand Cannabis Smoke
While not as well-studied as tobacco smoke, secondhand cannabis smoke may pose health risks, particularly in enclosed spaces. Preliminary research suggests possible effects include:
- Temporary intoxication (especially in children or pets)
- Lung irritation
- Increased exposure to harmful particulates
Further research is needed to fully understand the effects of passive exposure.
Takeaway: Is Cannabis Good or Bad for Your Health?
Cannabis has proven benefits for pain relief, appetite stimulation, and nausea control, particularly when used under medical supervision. It also shows promise in treating neurological disorders and managing certain mental health symptoms.
However, it is not a one-size-fits-all remedy. For some users—especially adolescents, pregnant women, and individuals with a predisposition to mental health disorders—cannabis can pose significant risks.
As the market grows and more research becomes available, the emphasis must remain on education, responsible use, and medically guided treatment. Choosing the right form, dose, and frequency is essential to maximizing cannabis’ benefits while minimizing its potential harms.
-
Legalization And Regulations6 months ago
Rhode Island Finalizes Cannabis Regulations Ahead of Full Market Transition
-
Legalization And Regulations6 months ago
Florida’s Amendment 3 Fails: Recreational Marijuana Legalization Rejected Despite Trump’s Support
-
Cannabis Product Reviews6 months ago
Dr. Greenthumb’s x G Pen: A Compact Vaporizer With Big Style and Even Bigger Performance
-
Cannabis Industry News7 months ago
Leadership Shakeup in NYC Sparks Questions About the Future of Urban Cannabis Programs
-
Dispensaries5 months ago
3 Dispensaries in New Mexico That Are Revolutionizing the Scene
-
Cannabis Industry News7 months ago
Tariffs and the Cannabis Supply Chain: How U.S. Businesses Are Adapting to Economic Headwinds
-
Cannabis Product Reviews7 months ago
Exploring the Entourage Effect: A Closer Look at The Terpene Store’s Natural Products Sample Pack
-
Dispensaries6 months ago
Top 3 Trendsetting Dispensaries in Michigan for 2025